Positive Phase II data bolster unoprostone's promise for retinitis pigmentosa
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals/R-Tech Ueno 's unoprostone isopropyl (UF-021) looks set to maintain its position as one of the frontrunner drug candidates for retinitis pigmentosa (RP) following the release of generally positive data from a Japanese Phase II trial.